Streetbeat News

TARO

Taro Pharmaceutical Industries

http://www.taro.com

CEO

Uday Baldota

Employees

1,339

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Open

42.97

Mkt cap

1.6B

Volume

147K

High

42.98

P/E Ratio

30.05

52-wk high

45.76

Low

42.94

Div yield

N/A

52-wk low

32.67

Taro Pharmaceutical Indus (NYSE:TARO) is scheduled to release its quarterly earnings report on Thursday, 2024-01-25, with analysts expecting an EPS of $0.30. Investors are looking for an earnings beat and positive guidance for future growth. Historically, TARO's stock price has shown varied reactions to past earnings performances, with a 2.3% drop after beating EPS last quarter. Shares are currently trading at $42.07, up 37.71% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 7:01 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Taro Pharmaceutical Industries (NYSE:TARO) from Buy to Neutral while maintaining the price target at $43.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:15 am

Taro Pharmaceutical has entered into a definitive merger agreement with Sun Pharma, where Sun Pharma will acquire all outstanding ordinary shares of Taro for $43 per share. This acquisition price represents a 48% premium over the unaffected share price on May 25, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 9:32 pm

Taro Pharmaceutical Indus (NYSE:TARO) reported Q2 2023 earnings of $0.38 per share, beating the analyst consensus estimate of $0.18 by 111.11%. However, this is a 42.42% decrease from the same period last year. The company's quarterly sales of $148.20 million missed the analyst consensus estimate of $161.14 million by 8.03%, but it's a 13.57% increase from the same period last year.

Portfolio Pulse from saritha@benzinga.com

October 26, 2023 | 9:11 pm

Taro Pharmaceutical Indus (NYSE:TARO) is set to release its latest quarterly earnings report on October 26, 2023. Analysts estimate an earnings per share (EPS) of $0.18. The company's past performance shows a beat in EPS last quarter, followed by a 0.11% increase in share price. The stock is currently trading at $33.5, with a 1.55% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

October 25, 2023 | 5:02 pm

Taro Pharmaceutical Indus (NYSE:TARO) reported Q1 earnings of $0.27 per share, a 27.03% decrease YoY. However, the company's sales increased by 1.42% to $158.89 million.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 6:40 am

Nvidia shares are trading higher by over 5% after the company announced it would build the Israel-1 generative AI cloud supercomputer. Other stocks moving in Tuesday's mid-day session include QualTek Services, T2 Biosystems, Aclarion, Arlington Asset Investment Corp, and GreenLight Biosciences Holdings.

Portfolio Pulse from Lisa Levin

May 30, 2023 | 5:27 pm

Sun Pharmaceutical is considering making a proposal to acquire all outstanding ordinary shares of Taro Pharmaceuticals, causing Taro's shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 3:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.